| Literature DB >> 28668900 |
Kohei Miyata1, Fusanori Yotsumoto1, Satoshi Fukagawa1, Chihiro Kiyoshima1, Nam Sung Ouk1, Daichi Urushiyama1, Tomohiro Ito1, Takahiro Katsuda1, Masamitsu Kurakazu1, Ryota Araki1, Ayako Sanui1, Daisuke Miyahara1, Masaharu Murata1, Kyoko Shirota1, Hiroshi Yagi2, Tadao Takono3, Kiyoko Kato2, Nobuo Yaegashi4, Kohei Akazawa5, Masahide Kuroki6, Shin'ichiro Yasunaga6, Shingo Miyamoto7.
Abstract
Ovarian cancer is the most lethal malignancy among gynaecological cancers. Although many anticancer agents have been developed for the treatment of ovarian cancer, it continues to have an extremely poor prognosis. Heparin-binding epidermal growth factor-like grown factor (HB-EGF) has been reported to be a rational therapeutic target for ovarian cancer. Here, we evaluated the clinical significance of serum HB-EGF by examining the association between prognosis and serum HB-EGF levels in patients with primary ovarian cancer. We found that high serum HB-EGF concentrations were significantly associated with poor prognosis in a combined cohort of patients with all stages of ovarian cancer, as well as in a subset of patients with advanced disease. In addition, serum HB-EGF levels increased as the cancer advanced. These data suggest that serum HB-EGF may be a target for the design of novel therapies for ovarian cancer. CopyrightEntities:
Keywords: ELISA; HB-EGF; companion diagnostics; ovarian cancer
Mesh：
Substances：
Year: 2017 PMID： 28668900 DOI： 10.21873/anticanres.11779
Source DB: PubMed Journal: Anticancer Res ISSN： 0250-7005 Impact factor: 2.480